Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.71 USD | +0.54% | -0.27% | +21.64% |
Sales 2024 * | - | Sales 2025 * | 40.87M 3.41B | Capitalization | 312M 26.03B |
---|---|---|---|---|---|
Net income 2024 * | -231M -19.26B | Net income 2025 * | -246M -20.51B | EV / Sales 2024 * | - |
Net cash position 2024 * | 543M 45.26B | Net cash position 2025 * | 448M 37.39B | EV / Sales 2025 * | -3.33 x |
P/E ratio 2024 * |
-1.34
x | P/E ratio 2025 * |
-1.27
x | Employees | 75 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.54% |
Latest transcript on Atea Pharmaceuticals, Inc.
1 day | +0.54% | ||
1 week | -0.27% | ||
Current month | -8.17% | ||
1 month | -1.59% | ||
3 months | -3.39% | ||
6 months | +21.24% | ||
Current year | +21.64% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 68 | 01/12/01 | |
Andrea Corcoran
DFI | Director of Finance/CFO | 61 | 01/13/01 |
Maria Horga
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 01/19/01 |
Barbara Duncan
BRD | Director/Board Member | 59 | 01/20/01 |
Chief Executive Officer | 68 | 01/12/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 3.71 | +0.54% | 143,066 |
25/24/25 | 3.69 | -0.27% | 174,652 |
24/24/24 | 3.7 | -0.80% | 196,517 |
23/24/23 | 3.73 | +1.63% | 180,547 |
22/24/22 | 3.67 | -1.34% | 345,154 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.64% | 312M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- AVIR Stock